Patents by Inventor Lars Fogh Iversen

Lars Fogh Iversen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6262044
    Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: July 17, 2001
    Assignees: Novo Nordisk A/S, Ontogen Corporation
    Inventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda